Clinical Trials
24 trialsNCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04514497 2026-05-19
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02595931 2026-05-13
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01787500 2026-04-23
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT05382559 2026-04-14
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05838768 2026-03-24
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Novartis
Phase 1 Active not recruiting
NCT05694715 2026-03-17
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco
Phase 1 Recruiting
NCT04329494 2025-12-10
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00576654 2025-04-15
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT04641871 2024-06-26
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT02049593 2022-09-26
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT02801097 2022-05-17
PAYLOAD
EpicentRx, Inc.
Phase 1 Terminated
NCT01485744 2020-08-04
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT02677116 2020-05-20
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01336985 2019-12-17
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02069704 2019-07-23
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
mAbxience Research S.L.
Phase 1 Completed
NCT00507091 2016-08-25
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
Sanofi
Phase 1 Completed
NCT00563316 2016-04-12
Effect of Panitumumab on the Pharmacokinetics of Irinotecan
Amgen
Phase 1 Completed
NCT02283359 2016-01-15
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT01434069 2015-12-24
Phase I Trial of Combination of FOLFIRI and SOM 230
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00506207 2007-07-25
TIROX
National Cancer Center, Korea
Phase 1 Unknown